Steady Progress in Multiple Myeloma: Applying New Data and Updated Guidelines Throughout Treatment

This activity's goal is to improve the knowledge, competence, and confidence of learners to integrate new and emerging therapies into practice to improve clinical outcomes in patients with multiple myeloma.

Recorded Presentations from the NCCN 2025 Annual Congress: Hematologic Malignancies™

This congress focuses on updates to the NCCN Guidelines®, new and emerging therapeutic agents, and practical management strategies to ensure optimal patient outcomes.

Myeloma Masterclass: Applying the Latest Guidelines for Evidence-Based, Equitable Care
In this certified on-demand webcast, experts discuss the latest guidelines for the management of newly diagnosed, smoldering, and relapsed/refractory multiple myeloma, including use of bispecific antibodies, antibody–drug conjugates, CAR T-cell therapies, and novel therapeutics.
Steady Progress in Multiple Myeloma: Applying New Data and Updated Guidelines Throughout Treatment

Click the Register/Take Course button to complete the evaluation and get your certificate.

Recorded Presentation from Optimizing Patient Outcomes - Transitioning CAR T-Cell and Bispecific Therapies to the Outpatient Setting
Treatment with CAR T-cell and bispecific therapies is a labor-intensive process and requires substantial interprofessional collaboration. Additional education and training of all involved clinical staff is essential to managing these patients as well as their subsequent toxicities.
Optimizing Patient Outcomes - Transitioning CAR T-Cell and Bispecific Therapies to the Outpatient Setting
Treatment with CAR T-cell and bispecific therapies is a labor-intensive process and requires substantial interprofessional collaboration. Additional education and training of all involved clinical staff is essential to managing these patients as well as their subsequent toxicities.
Updates to Management of Multiple Myeloma
With the introduction of many new therapies, the management of multiple myeloma (MM) is rapidly changing. A uniform treatment approach cannot be applied to all patients.
Myeloma Masterclass: Applying the Latest Guidelines for Evidence-Based, Equitable Care
Live satellite symposium with a panel of experts discussing current guidelines and latest clinical evidence for the management of patients with multiple myeloma including expert guidance to help inform treatment decisions and therapy sequencing.
Archived NCCN Tumor Boards: Treatment Options and Navigating Sequencing of Therapies in Relapsed/Refractory Multiple Myeloma
With the introduction of many new therapies, the management of multiple myeloma is rapidly changing. A uniform treatment approach cannot be applied to all patients.
NCCN Guidelines® Insights - Multiple Myeloma, Version 1.2025
The NCCN Guidelines for Multiple Myeloma (MM) provide recommendations for diagnosis, initial workup, treatment, follow-up, and supportive care for patients with MM. These NCCN Guidelines Insights highlight the important updates and changes specific to systemic therapy for patients with newly diagnosed as well as previously treated MM included in Version 1.2025 of the NCCN Guidelines for MM.

Pages

Subscribe to RSS - Multiple Myeloma